U.S. Shingles Vaccine Market (2025 - 2033) Size, Share & Trends Analysis Report By Product (Shingrix, Zostavax, SkyZoster), By Vaccine Type (Recombinant Vaccine, Live Attenuated Vaccine), By End Use, And Segment Forecasts

U.S. Shingles Vaccine Market Size & Trends

The U.S. Shingles Vaccine market size was valued at USD 3.41 billion in 2024 and is projected to register a CAGR of 10.17% during 2025 - 2033. Growth in the market is primarily driven by the expanding elderly population, increased awareness of shingles-related complications, and the broader adoption of recombinant vaccine technologies. In preventive healthcare, shingles vaccines are crucial for reducing disease burden among adults aged 50 and above, particularly those with compromised immune function. The introduction of two-dose, adjuvanted formulations has improved long-term efficacy and coverage. In addition, ongoing R&D efforts around mRNA-based shingles vaccines and improved immunization schedules continue to support uptake and market expansion.

The rising need for long-lasting protection in older adults has led to notable improvements in vaccine design, focusing on enhanced immune response and safety. Recombinant vaccines such as Shingrix have shown strong performance in clinical settings. They are widely recommended across the U.S. adult population. Newer vaccine candidates, including mRNA-based formulations, are being developed to offer simpler dosing, broader immune protection, and more efficient production timelines. These innovations are expected to strengthen the market over the coming years, especially as demand for preventive care grows.

Supportive healthcare infrastructure and public health policies also shape the U.S. shingles vaccine landscape. Federal initiatives, adult immunization campaigns, and Medicare coverage for shingles vaccination have improved access and reduced financial barriers for older adults. As the number of immunocompromised individuals rises due to cancer, organ transplants, and chronic conditions, shingles vaccination has become an essential part of clinical guidelines. In response, healthcare systems are expanding outreach, integrating adult vaccines into regular care visits, and aligning with broader public health goals.

Continued investment in R&D and product innovation is further enhancing vaccine availability. Public-private collaborations and funding support are helping accelerate clinical trials and promote the use of advanced technologies like adjuvant systems and mRNA platforms. In addition, real-world studies generate evidence of long-term efficacy, helping drive vaccine confidence and adoption. While Shingrix dominates the current U.S. market, growing global interest in shingles vaccines is reflected in new product approvals elsewhere, such as SKYZoster's approval in Malaysia in 2023. Such developments signal potential for future market expansion and competition.

The growing emphasis on adult vaccination, rising disease burden, and technological progress are expected to sustain strong growth in the U.S. Shingles Vaccine Market. The industry focuses on improving immune response, reducing dosing complexity, and expanding outreach through private and public health channels.

To capture evolving trends and inform strategy, key market dynamics are outlined below:

Market Dynamics U.S. Shingles Vaccine Market

This overview reflects how a mix of demographic trends, technological innovation, and policy support is influencing the direction of the U.S. shingles vaccine market.

Market Concentration & Characteristics

Innovation in the U.S. shingles vaccine market is centered around shifting from older live vaccines to newer recombinant and mRNA-based options. These next-generation vaccines offer better protection, fewer side effects, and longer-lasting immunity. Some companies are working on freeze-dried (lyophilized) mRNA vaccines to improve shelf life and make distribution easier. Features like prefilled syringes and digital tools for tracking doses are also being introduced to improve convenience and safety. Such developments support more efficient vaccination, especially for older adults and those with weaker immune systems.

Mergers and acquisitions directly related to shingles vaccines are limited. Most activity in this area is part of larger deals involving full vaccine portfolios or partnerships for mRNA technology. Instead of frequent acquisitions, companies are focusing on licensing agreements and joint development for improving adjuvants and delivery systems. While shingles vaccines remain a smaller part of the overall vaccine market, companies are still investing in expanding their pipelines and improving reach through strategic collaborations.

Regulatory oversight is a key part of the shingles vaccine market, especially from agencies like the U.S. FDA. Recombinant and adjuvanted vaccines follow clearly defined approval processes, and continued monitoring is required even after they reach the market. Programs like fast-track approvals and updated CDC guidelines help vaccines reach older adults faster. However, managing cold storage requirements and meeting different documentation rules can make rollout complex. These challenges highlight the importance of clearer and more aligned regulatory processes to improve access across regions.

The U.S. shingles vaccine market is growing with new products focused on improving ease of use and broader protection. mRNA-based shingles vaccines are in clinical trials and are expected to bring benefits such as simpler storage and stronger immune response. Companies are also exploring combination vaccines and co-administration with other adult vaccines, helping reduce the number of visits for patients. These efforts aim to reach more people, reduce delays in second-dose completion, and improve vaccine durability.

In the U.S., shingles vaccination programs are well-established in urban areas, but efforts are growing to improve access in rural and underserved regions. Pharmacies, primary care clinics, and mobile health units are being used to reach more older adults. Medicare coverage and awareness campaigns are also helping expand vaccine access. These regional strategies aim to close the gap in immunization coverage and ensure timely vaccination for those at higher risk, especially as the country’s aging population continues to grow.

Product Insights

The Shingrix segment dominated the U.S. shingles vaccine market in 2024, accounting for the largest revenue share. This strong position stems from its recombinant, adjuvanted formulation, which offers high efficacy and extended protection compared to older live attenuated vaccines. The CDC's broad endorsement and inclusion in Medicare-covered adult vaccination schedules have significantly boosted its adoption in clinical and pharmacy settings. Healthcare providers and patients favor Shingrix because of its demonstrated ability to reduce shingles incidence and prevent postherpetic neuralgia among older adults.

A key instance underlining its leading role occurred in 2024, when the Advisory Committee on Immunization Practices (ACIP) reaffirmed its recommendation of Shingrix-two doses-for adults aged 50+ and also extended the recommendation to immunocompromised adults aged 19 and above. This reaffirmation reflects strong real-world evidence confirming the vaccine's safety and effectiveness, solidifying its continued dominance in the U.S. market.

The SKYZoster segment is expected to grow steadily in the U.S. shingles vaccine market over the forecast period. This growth is supported by increasing regulatory approvals and interest in expanding vaccine choices beyond the current market leader. SKYZoster is a recombinant vaccine that offers better safety and protection than older live vaccines, making it a potential option for adult immunization programs. Recent developments, such as product approvals in multiple countries and rising interest in alternative recombinant options, are drawing attention to its future potential in the U.S. market.

Vaccine Type Insights

The recombinant vaccine segment held the largest share of the U.S. shingles vaccine market in 2024. This strong position is due to recombinant vaccines' higher safety and effectiveness than older live attenuated vaccines. Products like Shingrix use recombinant technology to create a strong immune response, especially for older adults and people with weaker immune systems. The CDC widely recommends these vaccines and includes them in national vaccination programs, helping drive their continued use.

In the U.S., recombinant vaccines are preferred because they provide long-lasting protection and avoid the risks associated with live-virus vaccines, making them safer for immunocompromised populations. Ongoing research is focused on improving adjuvants and simplifying storage and delivery methods, such as using prefilled syringes and mRNA-based platforms. These developments are expected to keep the segment in a leading position as more adults seek protection from shingles and related complications. In addition, continued public health campaigns and Medicare support are helping to increase awareness and access to recombinant vaccines across different care settings.

The live attenuated vaccine segment is expected to grow steadily in the U.S. shingles vaccine market over the forecast period. These vaccines, which use a weakened form of the varicella-zoster virus to build immunity, were widely used before recombinant vaccines like Shingrix became the standard. While no longer the preferred option, live attenuated vaccines have a long-standing safety profile and offer the benefit of single-dose administration, which may still appeal to certain patient groups.

In the U.S., their usage has declined due to limitations in older adults and immunocompromised individuals, for whom recombinant vaccines are considered safer and more effective. However, recent findings have renewed interest in their broader health potential. In April 2025, a Stanford-led study using data from Wales found that individuals who received the live-attenuated Zostavax vaccine had a 20% lower risk of developing dementia over a seven-year period. This has drawn attention to possible long-term benefits beyond shingles prevention.

End Use Insights

The private healthcare settings segment dominated the U.S. shingles vaccine market, accounting for the largest revenue share in 2024. This segment includes private hospitals, specialty clinics, retail pharmacies, and corporate wellness programs, which offer easier access and quicker service. Private healthcare providers play a significant role in shingles vaccination in urban areas and high-income populations due to higher awareness and greater willingness to pay for timely and convenient care.

Many individuals in the U.S. choose private settings for shingles vaccination to avoid wait times and ensure flexibility in scheduling. These settings also support broader vaccine availability, especially when government-funded programs are limited to specific age groups or conditions. The presence of adult immunization services at retail pharmacy chains and large health networks has further strengthened the reach of this segment, helping drive consistent demand throughout the year.

The government healthcare settings segment is projected to grow steadily in the U.S. shingles vaccine market over the forecast period. This segment includes public hospitals, community health centers, and federally supported vaccination programs that provide shingles vaccines to eligible adults, often at no cost or through Medicare coverage. These services are essential for older adults and immunocompromised individuals who may not have access to private careGrowth in this segment is supported by government efforts to prevent shingles-related complications and reduce long-term healthcare costs. Programs like Medicare Part D help cover shingles vaccination for adults aged 50 and older, while public health campaigns continue raising awareness about the benefits of adult immunizations. With more people becoming eligible and outreach expanding, the role of government-supported vaccination is expected to strengthen across the country.

Key U.S. Shingles Vaccine Company Insights

Some of the key players in the U.S. shingles vaccine market are adopting a range of strategies to strengthen their market position. These efforts focus on expanding vaccine availability, improving immunization coverage among adults, and maintaining competitiveness in a market shaped by evolving public health priorities and technological innovation.

Recent Developments

• In March 2025, AIM Vaccine Co., Ltd. announced that its independently developed mRNA shingles vaccine received clinical trial approval from the U.S. Food and Drug Administration (FDA). Alongside this, the company also received FDA approval to initiate trials for its mRNA RSV vaccine. These approvals mark a significant step forward in expanding the shingles vaccine pipeline in the U.S., highlighting the growing interest in mRNA-based platforms for adult immunization. The use of AI in AIM’s mRNA development process further underscores the integration of advanced technologies in next-generation vaccine innovation.

• In March 2025, the FDA approved a supplemental Biologics License Application (BLA) for Shingrix, expanding its prescribing information to include new data from Study Zoster‑049 on long-term vaccine effectiveness.

• In January 2025, the U.S. Food and Drug Administration (FDA) accepted for review a regulatory submission from GSK for a prefilled syringe formulation of Shingrix. This new presentation is intended to simplify vaccine administration and improve convenience for healthcare providers and patients. 

U.S. Shingles Vaccine Market Report Scope

U.S. Shingles Vaccine Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the U.S. Shingles Vaccine market on the product,vaccine type, and end use:

• Product Outlook (Revenue in USD Million, 2021 - 2033)

  • Shingrix

  • Zostavax

  • SKYZoster

• Vaccine Type Outlook (Revenue in USD Million, 2021 - 2033)

  • Recombinant Vaccine

  • Live Attenuated Vaccine

• End Use Outlook (Revenue in USD Million, 2021 - 2033)

  • Private Healthcare Settings

  • Government Healthcare Settings